Cargando…

Effectiveness of Ribavirin and Corticosteroids for Severe Acute Respiratory Syndrome

OBJECTIVE: Ribavirin and corticosteroids were used widely as front-line treatments for severe acute respiratory syndrome; however, previous evaluations were inconclusive. We assessed the effectiveness of ribavirin and corticosteroids as the initial treatment for severe acute respiratory syndrome usi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lau, Eric H.Y., Cowling, Benjamin J., Muller, Matthew P., Ho, Lai-Ming, Tsang, Thomas, Lo, Su-Vui, Louie, Marie, Leung, Gabriel M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093860/
https://www.ncbi.nlm.nih.gov/pubmed/19958895
http://dx.doi.org/10.1016/j.amjmed.2009.07.018
_version_ 1783510363243806720
author Lau, Eric H.Y.
Cowling, Benjamin J.
Muller, Matthew P.
Ho, Lai-Ming
Tsang, Thomas
Lo, Su-Vui
Louie, Marie
Leung, Gabriel M.
author_facet Lau, Eric H.Y.
Cowling, Benjamin J.
Muller, Matthew P.
Ho, Lai-Ming
Tsang, Thomas
Lo, Su-Vui
Louie, Marie
Leung, Gabriel M.
author_sort Lau, Eric H.Y.
collection PubMed
description OBJECTIVE: Ribavirin and corticosteroids were used widely as front-line treatments for severe acute respiratory syndrome; however, previous evaluations were inconclusive. We assessed the effectiveness of ribavirin and corticosteroids as the initial treatment for severe acute respiratory syndrome using propensity score analysis. METHODS: We analyzed data on 1755 patients in Hong Kong and 191 patients in Toronto with severe acute respiratory syndrome using a generalized propensity score approach. RESULTS: The adjusted excess case fatality ratios of patients with severe acute respiratory syndrome receiving the combined therapy of ribavirin and corticosteroids within 2 days of admission, compared with those receiving neither treatment within 2 days of admission, were 3.8% (95% confidence interval, −1.5 to 9.2) in Hong Kong and 2.1% (95% confidence interval, −44.3 to 48.5) in Toronto. CONCLUSIONS: Our results add strength to the hypothesis that the combination of ribavirin and corticosteroids has no therapeutic benefit when given early during severe acute respiratory syndrome infection. Further studies may investigate the effects of these treatments later in disease course.
format Online
Article
Text
id pubmed-7093860
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-70938602020-03-25 Effectiveness of Ribavirin and Corticosteroids for Severe Acute Respiratory Syndrome Lau, Eric H.Y. Cowling, Benjamin J. Muller, Matthew P. Ho, Lai-Ming Tsang, Thomas Lo, Su-Vui Louie, Marie Leung, Gabriel M. Am J Med Article OBJECTIVE: Ribavirin and corticosteroids were used widely as front-line treatments for severe acute respiratory syndrome; however, previous evaluations were inconclusive. We assessed the effectiveness of ribavirin and corticosteroids as the initial treatment for severe acute respiratory syndrome using propensity score analysis. METHODS: We analyzed data on 1755 patients in Hong Kong and 191 patients in Toronto with severe acute respiratory syndrome using a generalized propensity score approach. RESULTS: The adjusted excess case fatality ratios of patients with severe acute respiratory syndrome receiving the combined therapy of ribavirin and corticosteroids within 2 days of admission, compared with those receiving neither treatment within 2 days of admission, were 3.8% (95% confidence interval, −1.5 to 9.2) in Hong Kong and 2.1% (95% confidence interval, −44.3 to 48.5) in Toronto. CONCLUSIONS: Our results add strength to the hypothesis that the combination of ribavirin and corticosteroids has no therapeutic benefit when given early during severe acute respiratory syndrome infection. Further studies may investigate the effects of these treatments later in disease course. Elsevier Inc. 2009-12 2009-12-02 /pmc/articles/PMC7093860/ /pubmed/19958895 http://dx.doi.org/10.1016/j.amjmed.2009.07.018 Text en Copyright © 2009 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Lau, Eric H.Y.
Cowling, Benjamin J.
Muller, Matthew P.
Ho, Lai-Ming
Tsang, Thomas
Lo, Su-Vui
Louie, Marie
Leung, Gabriel M.
Effectiveness of Ribavirin and Corticosteroids for Severe Acute Respiratory Syndrome
title Effectiveness of Ribavirin and Corticosteroids for Severe Acute Respiratory Syndrome
title_full Effectiveness of Ribavirin and Corticosteroids for Severe Acute Respiratory Syndrome
title_fullStr Effectiveness of Ribavirin and Corticosteroids for Severe Acute Respiratory Syndrome
title_full_unstemmed Effectiveness of Ribavirin and Corticosteroids for Severe Acute Respiratory Syndrome
title_short Effectiveness of Ribavirin and Corticosteroids for Severe Acute Respiratory Syndrome
title_sort effectiveness of ribavirin and corticosteroids for severe acute respiratory syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093860/
https://www.ncbi.nlm.nih.gov/pubmed/19958895
http://dx.doi.org/10.1016/j.amjmed.2009.07.018
work_keys_str_mv AT lauerichy effectivenessofribavirinandcorticosteroidsforsevereacuterespiratorysyndrome
AT cowlingbenjaminj effectivenessofribavirinandcorticosteroidsforsevereacuterespiratorysyndrome
AT mullermatthewp effectivenessofribavirinandcorticosteroidsforsevereacuterespiratorysyndrome
AT holaiming effectivenessofribavirinandcorticosteroidsforsevereacuterespiratorysyndrome
AT tsangthomas effectivenessofribavirinandcorticosteroidsforsevereacuterespiratorysyndrome
AT losuvui effectivenessofribavirinandcorticosteroidsforsevereacuterespiratorysyndrome
AT louiemarie effectivenessofribavirinandcorticosteroidsforsevereacuterespiratorysyndrome
AT leunggabrielm effectivenessofribavirinandcorticosteroidsforsevereacuterespiratorysyndrome